全文获取类型
收费全文 | 7734篇 |
免费 | 436篇 |
国内免费 | 42篇 |
专业分类
耳鼻咽喉 | 89篇 |
儿科学 | 180篇 |
妇产科学 | 134篇 |
基础医学 | 990篇 |
口腔科学 | 185篇 |
临床医学 | 651篇 |
内科学 | 1951篇 |
皮肤病学 | 148篇 |
神经病学 | 679篇 |
特种医学 | 224篇 |
外科学 | 1307篇 |
综合类 | 57篇 |
一般理论 | 6篇 |
预防医学 | 455篇 |
眼科学 | 226篇 |
药学 | 413篇 |
中国医学 | 50篇 |
肿瘤学 | 467篇 |
出版年
2023年 | 72篇 |
2022年 | 73篇 |
2021年 | 355篇 |
2020年 | 200篇 |
2019年 | 288篇 |
2018年 | 353篇 |
2017年 | 221篇 |
2016年 | 214篇 |
2015年 | 229篇 |
2014年 | 383篇 |
2013年 | 430篇 |
2012年 | 712篇 |
2011年 | 679篇 |
2010年 | 387篇 |
2009年 | 320篇 |
2008年 | 510篇 |
2007年 | 508篇 |
2006年 | 452篇 |
2005年 | 434篇 |
2004年 | 362篇 |
2003年 | 354篇 |
2002年 | 300篇 |
2001年 | 35篇 |
2000年 | 23篇 |
1999年 | 32篇 |
1998年 | 34篇 |
1997年 | 26篇 |
1996年 | 21篇 |
1995年 | 20篇 |
1994年 | 11篇 |
1993年 | 17篇 |
1992年 | 14篇 |
1991年 | 14篇 |
1990年 | 9篇 |
1989年 | 6篇 |
1988年 | 12篇 |
1987年 | 7篇 |
1986年 | 6篇 |
1985年 | 8篇 |
1984年 | 6篇 |
1983年 | 7篇 |
1982年 | 5篇 |
1981年 | 11篇 |
1980年 | 6篇 |
1979年 | 7篇 |
1977年 | 4篇 |
1976年 | 7篇 |
1975年 | 5篇 |
1974年 | 4篇 |
1972年 | 4篇 |
排序方式: 共有8212条查询结果,搜索用时 15 毫秒
1.
2.
3.
Estefany I. Medina-Reyes Carolina Rodríguez-Ibarra Daniel Díaz-Urbina Alejandro Déciga-Alcaraz Normal L. Delgado-Buenrostro Yolanda I. Chirino José Pedraza-Chaverri 《Journal of applied toxicology : JAT》2022,42(8):1411-1419
Food-grade titanium dioxide (E171) is widely used as a food additive, and it is known that after oral consumption, E171 is translocated into the bloodstream reaching the highest titanium level at 6 h. E171 is accumulated in some organs triggering toxicity, but the effects on the blood parameters after oral consumption have been less studied. Recently, evidence shows that oral exposure to E171 induces behavioral signs of anxiety and depression. The relation between blood alterations and psychiatric disorders has been previously demonstrated. However, the oral exposure to E171 effects on alterations in blood parameters and effects linked to alterations in animal behavior has not been explored. In this short communication, we aimed to investigate the effects of E171 on specific blood parameters (hematocrit, hemoglobin, number of erythrocytes, and leukocytes) and anxiety and compulsive-like behavior in males and females orally exposed to ~5 mg/kg for 4 weeks. The results showed that E171 decreased hematocrit and hemoglobin in male but not in female mice while leukocyte and erythrocyte count remained unaltered. Oral consumption of E171 decreased the levels of anxiety-like behavior in females but not in male mice, while compulsive-like behavior was increased in both male and female mice. 相似文献
4.
5.
6.
7.
8.
Castaldelli-Maia João Mauricio Hofmann Caio Chagas Antonio Carlos Palandri Liprandi Alvaro Sosa Alcocer Alejandro Andrade Laura H. Wielgosz Andreas 《Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy》2021,35(3):441-454
Cardiovascular Drugs and Therapy - Major depressive disorder (MDD) and anxiety disorders (AD) are both highly prevalent among individuals with arrhythmia, ischemic heart disease, heart failure,... 相似文献
9.
Mariángeles González Fernández Elena Villamañán Inmaculada Jiménez-Nácher Francisco Moreno Chamaida Plasencia Francisco Gayá Alicia Herrero Alejandro Balsa 《Reumatología clinica》2021,17(6):335-342
ObjectiveTo assess the evolution of cost per patient/year and the cost per patient/year/drug in patients with rheumatoid arthritis (RA) receiving biological treatments. To analyze and quantify the factors influencing this evolution, such as the optimization of the biological drugs, the use of biosimilars, and official discounts and discounts obtained after negotiated procedures. In addition, to assess specific clinical parameters of disease activity in these patients.MethodsRetrospective, observational study conducted in a Spanish tertiary hospital. Adult patients diagnosed with RA under treatment from 2009 to 2017 were included.Results320, 270 and 389 patients were included in 2009, 2013 and 2017, respectively. The patient/year cost decreased from 10,789€ in 2009, 7491€ in 2013 to 7116€ in 2017. In 2017, due to the established competition, discounts of 14% and 29.5% were achieved on etanercept and its biosimilar; 11.5%, 17.8%, 17.9%, 17.3% on adalimumab, certolizumab, golimumab and tocilizumab IV respectively, and 24.6% and 43.1% on infliximab and its biosimilar. The percentage of patients optimized in 2017 was 35.2%. The annual saving in 2017 was 1,288,535€ (830,000€ due to dose optimization and/or administration regimens, 249,666€ corresponding to 7.5% of the official discount and 208,868€ after negotiated procedures).ConclusionThe annual cost per patient in RA decreased considerably due to different factors, such as discounts on the purchase of drugs due to official discounts and negotiated procedures, together with the optimization of therapies, the latter being the factor that contributed most to this decrease. 相似文献
10.